HSP90AA1 and melanoma: In the GSDME immunofluorescent assays, pre-treatment of melanoma cells with caspase-1 inhibitor VX-765 or pan-caspase inhibitor Z-VAD-FMK suppressed the GSDME activation induced by the combined Hsp90 and PI3K inhibitors (Figure 6C).